Company news
Pluri Inc. news in 2020
Pluri Inc.'s news releases, calls and decks from 2020, newest first.
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
December 8, 2020
Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
October 12, 2020
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
August 26, 2020
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
August 18, 2020
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
June 10, 2020
Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
May 4, 2020
Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
April 6, 2020
Decks in 2020
- Pluristem Therapeutics — Corporate Update (December 2020)
Corporate update · 15 slides · Dec 9, 2020